These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28604554)

  • 61. ANCA-associated vasculitic neuropathy during treatment with ipilimumab.
    Villarreal-Compagny M; Iglesias P; Marco-Hernández J; Milisenda JC; Casanova-Molla J; Hernández-Rodríguez J; Puig S; Carrera C; Prieto-González S
    Rheumatology (Oxford); 2020 Jan; 59(1):251-252. PubMed ID: 31209477
    [No Abstract]   [Full Text] [Related]  

  • 62. Bilateral ipilimumab-induced posterior uveitis following treatment for metastatic choroidal melanoma.
    Tan AX; Ang A; Campbell WG; Fabinyi DC
    Clin Exp Ophthalmol; 2018 Sep; 46(7):819-821. PubMed ID: 29653019
    [No Abstract]   [Full Text] [Related]  

  • 63. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.
    Chaput N; Lepage P; Coutzac C; Soularue E; Le Roux K; Monot C; Boselli L; Routier E; Cassard L; Collins M; Vaysse T; Marthey L; Eggermont A; Asvatourian V; Lanoy E; Mateus C; Robert C; Carbonnel F
    Ann Oncol; 2017 Jun; 28(6):1368-1379. PubMed ID: 28368458
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma.
    Sundahl N; De Wolf K; Kruse V; Meireson A; Reynders D; Goetghebeur E; Van Gele M; Speeckaert R; Hennart B; Brochez L; Ost P
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):906-915. PubMed ID: 29485070
    [TBL] [Abstract][Full Text] [Related]  

  • 65. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
    Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
    [No Abstract]   [Full Text] [Related]  

  • 66. A Life-Threatening Cause of Colitis.
    Jaswani TS; Grider DJ; Bern MJ
    Gastroenterology; 2018 Jan; 154(1):35-36. PubMed ID: 28918915
    [No Abstract]   [Full Text] [Related]  

  • 67. Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
    Amode R; Baroudjian B; Kowal A; Jebali M; Allayous C; Bagot M; Madjlessi N; Roux J; Viguier M; Basset Seguin N; Porcher R; Pagès C; Lebbé C
    Melanoma Res; 2017 Apr; 27(2):110-115. PubMed ID: 27926587
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
    Ascierto PA; Del Vecchio M; Robert C; Mackiewicz A; Chiarion-Sileni V; Arance A; Lebbé C; Bastholt L; Hamid O; Rutkowski P; McNeil C; Garbe C; Loquai C; Dreno B; Thomas L; Grob JJ; Liszkay G; Nyakas M; Gutzmer R; Pikiel J; Grange F; Hoeller C; Ferraresi V; Smylie M; Schadendorf D; Mortier L; Svane IM; Hennicken D; Qureshi A; Maio M
    Lancet Oncol; 2017 May; 18(5):611-622. PubMed ID: 28359784
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Checkpoint Inhibitor-Associated Hypophysitis.
    Chang LS; Yialamas MA
    J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
    [No Abstract]   [Full Text] [Related]  

  • 70. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis.
    Bello E; Cohen JV; Mino-Kenudson M; Dougan M
    J Immunother Cancer; 2019 Feb; 7(1):41. PubMed ID: 30744698
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.
    Spänkuch I; Gassenmaier M; Tampouri I; Noor S; Forschner A; Garbe C; Amaral T
    Eur J Cancer; 2017 Aug; 81():203-205. PubMed ID: 28641200
    [No Abstract]   [Full Text] [Related]  

  • 72. Diet-dependent toxicity of ipilimumab in metastatic melanoma.
    Majenka P; Hoffmann M; Rötzer I; Dimitrakopoulou-Strauss A; Koschny R; Longerich T; Enk A; Hassel JC
    Eur J Cancer; 2019 Jan; 106():220-224. PubMed ID: 30528806
    [No Abstract]   [Full Text] [Related]  

  • 73. Ipilimumab treatment associated with myasthenic crises and unfavorable disease course.
    Derle E; Benli S
    Neurol Sci; 2018 Oct; 39(10):1773-1774. PubMed ID: 29948466
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma.
    Lee B; Wong A; Kee D; Neeson P; Shackleton M; McArthur G; Sandhu S
    Ann Oncol; 2016 Jun; 27(6):1174-1177. PubMed ID: 26861600
    [No Abstract]   [Full Text] [Related]  

  • 75. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
    Adler NR; Murray WK; Brady B; McCormack C; Pan Y
    Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
    [No Abstract]   [Full Text] [Related]  

  • 76. Ipilimumab-induced hypophysitis and ileocolitis: Serial pituitary MRI findings.
    Singh D; Hsu CC; Kwan GN; Bhuta S
    Neurol India; 2017; 65(1):165-166. PubMed ID: 28084260
    [No Abstract]   [Full Text] [Related]  

  • 77. Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy.
    Tietze JK; Angelova D; Heppt MV; Ruzicka T; Berking C
    Exp Dermatol; 2017 Jul; 26(7):622-629. PubMed ID: 27892653
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
    Martens A; Wistuba-Hamprecht K; Yuan J; Postow MA; Wong P; Capone M; Madonna G; Khammari A; Schilling B; Sucker A; Schadendorf D; Martus P; Dreno B; Ascierto PA; Wolchok JD; Pawelec G; Garbe C; Weide B
    Clin Cancer Res; 2016 Oct; 22(19):4848-4858. PubMed ID: 27169993
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 80. Ipilimumab for relapse after allogeneic transplantation.
    Baker H
    Lancet Oncol; 2016 Sep; 17(9):e374. PubMed ID: 27452141
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.